Researchers
in cancer proteases, basic cancer researchers, oncologists, those
working in the areas of bioinformatics, proteomics, cancer chemistry,
drug development
Table of contents:
Section 1: The Degradome and its analysis
Chapter 1: Protease Genomics and the Cancer Degradome
Xose S. Puente, Gonzalo R Ordonez & Carlos López-Otín
Chapter 2: The CLIP-CHIP: A focused oligonucleotide microarray
platform for transcriptone analysis for the complete human and murine
cancer degradomes.
Rheinhild Kappelhoff, Claire H.Wilson, & Christopher M. Overall
Chapter 3: The Hu/Mu ProtIn chip: A custom dual-species
Oligonucleotide Microarray for profiling degradome gene expression in
tumours and their microenvironment
Donald R.Scwartz, Kamiar Moin, Ekkehard Weber & Bonnie F Sloane
Chapter 4: Quantitative Real-Time PCR analysis of degradome gene expression
Caroline J Pennington, Robert K. Nuttall, Clara Sampieri -Ramirez, , Matthew Wallard, Simon Pilgrim & Dylan R. Edwards
Chapter 5: Identification of protease substrates by mass spectrometry approaches.
Mari Enoksson,Wenhong Zhu & Guy Salvesen
Chapter 6: Identification of protease substrates by mass spectrometry approaches – 2.
Anna Prudova, Ulrich auf dem Keller & Christopher M. Overall
Chapter 7: Activity based imaging and biochemical profiling tools for analysis of the cancer degradome.
Vincent Dive, Margot Paulick, J.Oliver McIntyre, Lynn M. Matrisan & Matthew Bogyo.
Chapter 8: Images of cleavage
Kamiar Moin,Mansoureh Sameni, Christopher Jedeszko, Quanwen Li, Mary B. Olive, Raymond R. Mattingly & Bonnie F. Sloane
Section 2: Insights into Protease function
Chapter 9: Proteolytic pathways: Intersecting cascades in cancer development
Nesrine I. Affara & Lisa M, Coussens
Chapter 10: Physiological functions of plasminogen activation: Effects of gene deficiences in humans and mice
Thomas H. Bugge
Chapter 11: The plasminogen activation system in tissue remodelling and cancer invasion
Kasper Almholt, Anna Juncker-Jensen, Kirsty Anne Green, Helene Solberg, Leif Roge Lund & John Rømer
Chapter 12: The urokinase plasminogen activator receptor as a target for cancer therapy
Silvia D’Alessio & Francesco Blasi
Chapter 13: The endocytic collagen receptor uPARAP/Endo 180 in cancer invasion and tissue remodelling
Thore Hillig, Lars H. Engelholm & Niels Behrendt
Chapter 14: Physiological and pathological functions of type II
transmembrane serine proteinases:Lessons from transgenic mouse models
and human disease-associated mutations.
Karin List & Thomas Bugge
Chapter 15: Analysis of cysteine cathepsin knockout mice in cancer models
Thomas Reinheckel, Vasilena Gocheva, Christoph Peters & Johanna A. Joyce
Chapter 16: In vitro and in vivo models of angiogenesis to dissect MMP functions.
Sarah Berndt, Françoise Bruyère, Maud Jost & Agnès Noël
Chapter 17: The surface transplantation model to study the tumour-host interface
Maud Jost, Silvia Vosseler, Silvia Blacher, Norbert E. Fusenig, Margareta Mueller & Agnes Noel
Chapter 18: Unravelling the roles of proteases in cell migration in vitro and in vivo
Jelena Gavrilovic & Xanthe Scott
Chapter 19: New insights into MMP function in adipogenesis
Kumari L Andarawewal & Marie-Christine Riol
Chapter 20: TIMPs:Extracellular Modifiers in Cancer Development
Aditya Murty,William Cruz-Munoz & Rama Khokha
Section 3: The interface between Proteolysis and Cell Signalling
Chapter 21: Invadopodia: Interface for Invasion
Susette C Mueller, Vira V. Artym & Thomas Kelly
Chapter 22: uPAR and proteases in mobilization of hematopoietic stem cells
Pia Ragno & Francesco Blasi
Chapter 23: The urokinase receptor (uPAR) and integrins constitute a cell migration signalosome
Bernard Degryse
Chapter 24: Measuring uPAR dynamics in live cells
Moreno Zamai, Gabriele Malengo & Valeria R. Caiolfa
Chapter 25: Janus-faced effects of broad-spectrum and specific MMP inhibition on metastasis
Charlotte Kopitz & Achim Kruger
Chapter 26: Cytokine Substrates: MMP regulation of inflammatory signalling molecules
Jennifer H. Cox & Christopher M. Overall
Chapter 27: Matrix metalloproteinases as key regulators of tumour:bone interaction
Conor C. Lynch & Lynn M. Matrisan
Section 4: The degradome as source of cancer diagnostic and prognostic markers
Chapter 28: The plasminogen activation system as a source of prognostic markers in cancer
Ib Jarle Christensen, Helle Pappot & Gunilla Hoyer-Hansen
Chapter 29: Cysteine cathepsins and cystatins as cancer biomarkers
Tamara T. Lah, Natasa Obermaja, Maria Beatriz Duran Alonso & Janko Kos
Chapter 30: Novel degradome markers in breast cancer
Caroline J. Pennington, Simon Pilgrim, Paul N Span Fred C. Sweep & Dylan R. Edwards
Chapter 31: Meta-analysis of gene expression microarray data: Degradome genes in healthy and cancer tissues
Kristiina Iljin, Sami Kilpinen, Johanna Ivaska & Olli Kallioniemi
Chapter 32: Degradome gene polymorphisms
Ross Laxton & Shu Ye
Chapter 33: TIMP-1 as a prognostic marker in colorectal cancer
Camilla Frederiksen, Anne Fog Lomholt,Hans Jorgen Nielsen & Nils Brunner
Section 5: Novel therapeutic strategies
Chapter 34: Structure and inhibition of the urokinase-type plasminiogen activator receptor (uPAR)
Benedikte Jacobsen, Magnus Kjaergaard, Henrik Gardsvoll & Michael Ploug
Chapter 35: Engineered antagonists of uPA and PAI-1
M. Patrizia Stoppelli, Lisbeth M, Andersen, Giuseppina Votta & Peter A. Andreasen
Chapter 36: MMP inhibitor clinical trials – the past present and future
Barbara Fingleton
Chapter 37: Tailoring TIMPs for selective metalloproteinase inhibition
Hideaki Nagase & Gillian Murphy
Chapter 38: Third Generation MMP Inhibitors: Recent advances in the development of highly selective inhibitors
Athanasios Yiotakis & Vincent Dive
Chapter 39: Protease activated delivery and Imaging systems
Gregg Fields
Chapter 40: Development of tumour selective and endoprotease-activated anticancer therapeutics
Jason H. Gill & Paul M. Loadman
Chapter 41: Targeting Degradome genes via engineered Viral Vectors
Risto Ala-aho, Andrew H. Baker & Veli-Matti Kahari
